
---
title: '口腔医疗白马突然跳水，什么原因？防护手套龙头回撤85%，业绩环比大幅改善的医药股出炉，融资客连续加仓5股'
categories: 
 - 金融
 - 证券时报网
 - 数据
headimg: 'https://data.stcn.com/djsj/202208/W020220815661666728508.jpeg'
author: 证券时报网
comments: false
date: Mon, 15 Aug 2022 18:21:00 GMT
thumbnail: 'https://data.stcn.com/djsj/202208/W020220815661666728508.jpeg'
---

<div>   
<p>医药生物行业今年以来遭融资净卖出225.81亿元，是净卖出额最高的行业。</p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600763" code="600763">通策医疗</a>今日低开后下探，收盘跌幅9.03%，最新股价跌破60日线、120日线等多个均线。与前一个交易日相比，公司A股市值缩水超过40亿元。</p><p style="text-align:center"><img data-galleryid data-ratio="1.3491666666666666" data-s="300,640" src="https://data.stcn.com/djsj/202208/W020220815661666728508.jpeg" data-type="jpeg" data-w="1200" data-imgqrcoded="1" width="500px" height="674.5370370370371px" style="width: 500px; height: 674.537px;" oldsrc="W020220815661666728508.jpeg" referrerpolicy="no-referrer"></p><p>从过往历史来看，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600763" code="600763">通策医疗</a>是医药生物行业少有的稳健白马之一，过去十四个年度营收和净利润连续增长，公司由此引来众多机构追捧。今年一季度末，机构持仓占流通股比例超过50%，葛兰旗下中欧医疗健康混合、中欧医疗创新股票型，高毅资产旗下高毅庆瑞6号瑞行基金等均重仓该股。</p><p>在本次大跌之前，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600763" code="600763">通策医疗</a>股价已调整较长时间，距离去年6月份创下的历史高点已逾一年。公司A股市值最高时超过1300亿元，目前市值不足440亿元，最新收盘价较历史高点回撤67.91%。</p><p><strong>多地开展口腔医疗服务价格调查</strong></p><p>消息面，8月12日晚间，国家医保局办公室发布《关于开展口腔种植收费和医疗服务价格调查登记工作的通知》，全面开展种植牙价格调查，为集采奠定基础。</p><p>此外，包括吉林省、湖南省、安徽省六安市、江西省南昌市等在内的多地医保局已发布口腔种植收费和医疗服务价格调查登记的通知。</p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS601099" code="601099">太平洋</a>证券之前的研究称，在种植牙手术的费用构成中，核心材料种植体、基台、等耗材的费用占比达到75%，剩下手术总费用的25%，则为治疗费。按照集采后耗材费用80%的降幅计算，原本花费1万元的种植牙总费用，在集采后7500元的各类耗材费用或降至1500元，如果占比25%的治疗费用不变，总费用则降至4000元，降幅可达60%。如此一来，对依赖高端客户为主的<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600763" code="600763">通策医疗</a>的商业模式将造成冲击。</p><p><strong>医药生物板块遭融资客甩卖</strong></p><p>在医药集采和疫情的双重影响下，医药板块今年的市场表现较为平淡。证券时报·数据宝统计，医药生物指数今年以来跌幅达到20%，跑输同期上证指数10个百分点。8股累计跌幅超过50%，包括<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=NEEQ832278" code="832278">鹿得医疗</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=NEEQ430047" code="430047">诺思兰德</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000150" code="000150">*ST宜康</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300273" code="300273">*ST和佳</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS688163" code="688163">赛伦生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603520" code="603520">司太立</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300677" code="300677">英科医疗</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ301201" code="301201">诚达药业</a>等。市值超千亿的医药股中，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300760" code="300760">迈瑞医疗</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600276" code="600276">恒瑞医药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600436" code="600436">片仔癀</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300122" code="300122">智飞生物</a>今年以来跌幅均超20%。</p><p style="text-align:center"><img data-ratio="1.1439205955334988" data-s="300,640" src="https://data.stcn.com/djsj/202208/W020220815661667336469.png" data-type="png" data-w="403" data-imgqrcoded="1" oldsrc="W020220815661667336469.png" referrerpolicy="no-referrer"></p><p>最新收盘价与2021年以来高点相比，医药股平均回撤幅度41.31%。凭借防护手套热销业绩猛增的<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300677" code="300677">英科医疗</a>，在2021年1月份市值一度突破千亿，不过从2021年第一季度起公司净利润增速明显下滑，今年一季度公司盈利降至亿元以下。与2021年创下的高点相比，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300677" code="300677">英科医疗</a>股价回撤幅度达到85.31%，是期间回撤最大的医药股。</p><p style="text-align:center"><img data-galleryid data-ratio="1.3341666666666667" data-s="300,640" src="https://data.stcn.com/djsj/202208/W020220815661670515458.jpeg" data-type="jpeg" data-w="1200" data-imgqrcoded="1" width="500px" height="667.1296296296297px" style="width: 500px; height: 667.13px;" oldsrc="W020220815661670515458.jpeg" referrerpolicy="no-referrer"></p><p>从资金面上来看，融资客陆续撤离医药生物板块。数据宝统计，医药生物行业今年以来遭融资净卖出225.81亿元，是净卖出额最高的行业，行业融资余额排名由第一降至第三。</p><p>医药生物指数在4月27日盘中创年内低点，在经过前几个月的大幅调整之后，部分医药股已大幅反弹。数据宝统计，98股4月27日至今涨幅超过20%。医药龙头之一<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600276" code="600276">恒瑞医药</a>反弹幅度达到33.54%，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000661" code="000661">长春高新</a>累计反弹64.57%，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000963" code="000963">华东医药</a>反弹42.1%。反弹幅度靠前的细分医药龙头还有<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600085" code="600085">同仁堂</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002007" code="002007">华兰生物</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300595" code="300595">欧普康视</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603939" code="603939">益丰药房</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002422" code="002422">科伦药业</a>等。</p><p><strong>业绩环比改善的医药股出炉</strong></p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600109" code="600109">国金证券</a>近日的一份研报指出，消费医疗行业第三季度、第四季度改善轨迹清晰，经营不断恢复；院内医疗景气度同样于三季度开始逐步恢复，同时医保集采控费预期逐步趋于稳健。投资策略上，自上而下、个股投资、价值成长的风格将与医疗板块现状更加契合。</p><p><a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS601555" code="601555">东吴证券</a>研报认为，在疫情考验下，医疗服务板块展现快速恢复能力与长期增长韧性，头部企业投资价值凸显。随着居民消费意识的不断提高，医疗服务赛道具备长期投资价值。尤其面对医保局控费等政策进一步推进，医疗服务作为避险赛道更值得投资。</p><p>从业绩数据来看，部分医药股第二季度业绩环比提升明显。数据宝统计，按照半年报、快报、预告净利润下限计算，第二季度盈利超亿元的医药股中，32股环比增速达到50%以上。环比增速最高的5只股票分别是<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600129" code="600129">太极集团</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600521" code="600521">华海药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" code="002821">凯莱英</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300633" code="300633">开立医疗</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300363" code="300363">博腾股份</a>等。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600129" code="600129">太极集团</a>预计上半年净利润约为1.2亿元，同比增长56%；与一季度相比，环比增幅达到502.52%。</p><p>在上述业绩环比大幅提升的医药股中，5股获得融资客连续加仓，分别是<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002422" code="002422">科伦药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002001" code="002001">新和成</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000423" code="000423">东阿阿胶</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603456" code="603456">九洲药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600566" code="600566">济川药业</a>。<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002422" code="002422">科伦药业</a>被加仓的周期最长，该股连续4周获融资客加仓，累计加仓金额1.07亿元。（数据宝 梁谦刚）</p><p style="text-align: center;"><img data-ratio="1.427402862985685" data-s="300,640" src="https://data.stcn.com/djsj/202208/W020220815661671865475.png" data-type="png" data-w="489" data-imgqrcoded="1" oldsrc="W020220815661671865475.png" referrerpolicy="no-referrer"></p>
  
</div>
            